Brief: Zydus Lifesciences Says Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement
BRIEF-Zydus Lifesciences Says Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement Aug 11 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS:
ZYDUS LIFESCIENCES - SENTYNL THERAPEUTICS AND MEREO BIOPHARMA ANNOUNCE OPTION AND LICENSE AGREEMENT
ZYDUS LIFESCIENCES - AGREEMENT FOR ALVELESTAT IN ALPHA-1 ANTITRYPSIN DEFICIENCYASSOCIATED LUNG DISEASE
ZYDUS LIFESCIENCES - SENTYNL GRANTED GLOBAL MANUFACTURING RIGHTS FOR ALVELESTAT AS PART OF AGREEMENT
Source text: ID:nnAZN4TDA4M
Further company coverage: ZYDU.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka